SkyView Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

SkyView Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-748	Closed	-$263K	–	760
2023 Q2	$263K	Sell	748 -1,318	-64%	-$444K	0.07%	336
2023 Q1	$651K	Buy	2,066 +708	+52%	+$212K	0.15%	175
2022 Q4	$392K	Sell	1,358 -712	-34%	-$217K	0.12%	239
2022 Q3	$599K	Buy	2,070 +364	+21%	+$105K	0.18%	190
2022 Q2	$481K	Buy	1,706 +376	+28%	+$101K	0.13%	243
2022 Q1	$347K	Sell	1,330 -14,920	-92%	-$3.54M	0.08%	320
2021 Q4	$269K	Buy	+16,250	New	+$3.16M	0.06%	356
2021 Q1	–	Sell	-1,303	Closed	-$308K	–	322
2020 Q4	$308K	Buy	+1,303	New	+$299K	0.15%	152

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SkyView Investment Advisors's VRTX Position: Q3 2023 in Review

SkyView Investment Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 748 shares — an estimated $263K sold.

SkyView Investment Advisors first reported a position in VRTX in Q4 2020 and held it in 8 quarters. The position peaked at $651K in Q1 2023. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

SkyView Investment Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
SkyView Investment Advisors sold 748 Vertex Pharmaceuticals shares in Q3 2023, an estimated $263K.
SkyView Investment Advisors first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 8 quarters.
SkyView Investment Advisors's Vertex Pharmaceuticals position peaked at $651K in Q1 2023.
1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on SkyView Investment Advisors's 13F filing for Q3 2023, filed 17 Nov 2023.